A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples